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Synthesis of Sulfonamide Conjugates of Cu(II), 
Ga(III), In(III), Re(V) and Zn(II) Complexes: Carbonic 
Anhydrase Inhibition Studies 
 
Jonathan R. Dilworth,*1  Sofia I. Pascu*2, Philip A. Waghorn,*1 Daniela Vullo,3 
Simon R. Bayly,1 Martin Christlieb,4  Xin Sun1 and Claudiu T. Supuran3 
Carbonic anhydrase IX (CA IX) is currently generating great interest as a marker of tumour 
hypoxia and a potential chemotherapeutic target. In order to test the principle that a CA IX 
inhibitor could be used for  targeting PET or SPECT metallic radioisotopes to tumours we have 
prepared a number of conjugates involving aryl-sulfonamides or an acetazolamide derivative 
linked to a range of copper, indium, rhenium, 99m-technetium and zinc complexes. 
Radiolabelled 64Cu and 99mTc analogues of the ‘cold’ Cu and some of the Re complexes were 
prepared in good radiochemical incorporation. Inhibition of various human carbonic 
anhydrase isoforms (I, II, IX and XII) was tested with the ‘cold’, non-radiolabelled complexes, 
and compared with an acetazolamide standard (AZA). The molecular structure of a new, tri-
sulfonated porphyrin-labeled sulfonamide was determined using synchrotron X-ray 
crystallography. 
 
 
 
 
Introduction 
Carbonic anhydrases (CA) are zinc metalloenzymes that catalyse the interconversion between CO2 and HCO3-, maintaining pH 
balance in blood plasma and transporting carbon dioxide out of tissue. Sixteen isoforms of carbonic anhydrase exist to date, 
located in the cytosol, mitochondria and cellular membranes.1 Four transmembrane isozymes are implicated in the control of 
cell proliferation and cellular transformation. Particular interest surrounds the transmembrane CA IX isozyme, which has been 
shown to be overexpressed in certain cancer lines including renal, cervical squamous, ovarian, colorectal, bladder and non-
small cell lung carcinoma. Strong association between CA IX expression and intra-tumoural hypoxia has also been 
demonstrated.2 At a molecular level the response to hypoxia is the stabilization and activation of the transcription factor HIF-
1α and its targets. Under normoxic conditions HIF-1α is hydroxylated and binds the ubiquitin ligase von Hippel –Lindau (VHL) 
protein, targeting the HIF-1α for degradation. Loss or mutation in VHL triggers the hypoxic phenotype. The tumour associated 
upregulation of CA IX is the result of a strong transcriptional activation of the CA9 gene by HIF-1α.3 Studies on non-small cell 
lung carcinomas have shown CA IX association with proteins involved in angiogenesis, apoptosis inhibition and cell-cell 
adhesion disruption suggesting a strong relationship of this enzyme to a poor clinical outcome.4 Therefore, current research 
interest focuses in the development of CA inhibitors as an approach to the treatment of cancers where CA IX is over- expressed. 
Similar interest surrounds CA XII, a second tumour associated CA isozyme which has been identified in renal cell carcinoma.5 It 
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is similarly regulated by tumour hypoxia but by different biochemical pathways to the CA IX isozyme.3 Although it is less 
effective as a catalyst for CO2 hydration compared to CA IX, its catalytic activity is associated with the acidification of the tumour 
environment under hypoxia. The inhibition of these tumour associated CA isozymes could represent a novel therapeutic 
approach for the management of hypoxic tumours which over- express these proteins.6,7  
Selectivity for CA IX over the other CA enzymes has been investigated through docking studies / molecular modeling and X-ray 
crystal structure analysis8 and it was found that the guanidine moiety of an arginine residue is specific to CA IX enzyme, which 
also has a larger active site than the CA I and CA II isozymes.8 Inhibition of CA by arylsulfonamides was a matter of intense 
investigation and the Supuran group has carried out some comprehensive screening studies on libraries of sulfonamides to 
find the most selective compounds for CA binding. Inhibition studies with a series of aromatic and heterocyclic sulfonamides 
showed that CA IX and CA XII are sulfonamide avid.9,10 4-(2-Aminoethyl) benzenesulfonamide (ABS) was shown to be an 
efficient and specific CA IX inhibitor with an approximate selectivity of more than 60 fold for CA IX over the CA I isozyme. 
Another sulfonamide derivative acetazolamide (AZA), a known inhibitor of CA IX, is a clinically approved drug (Diamox)11 with 
a strong binding affinity for CA IX and CA XII in comparison with the CA I and CA II enzymes.3,9  
 
Figure 1: Schematic representations of: acetazolamide (AZA), 4-(2-aminoethyl) benzenesulfonamide (ABS), fluorescein-thioureido-ethyl-
sulfonamide (FTES) and of three known reagents radiolabelled with [18-F],  [11-C] or [64-Cu] for PET imaging in vivo. 
Derivatives of AZA and ABS have been investigated as bifunctional chelators for imaging. However only very few examples of 
these derivatives labelled with radioisotopes have been reported thus far (Figure 1). 12 Preliminary radiolabelling studies with 
2-[18F]-3,5,6-trifluor-3’-sulphamoylbenzanilide have demonstrated good correlation between 18F retention and the level of the 
CA IX expression in vitro and favourable tumour to muscle uptake ratios for CA IX expressing HT-29 xenograft models in vivo.13 
Bifunctional compounds of these sulfonamides have been developed to incorporate a fluorescent tag in the form of fluorescein 
14 to enable in vitro fluorescence imaging. Upon incorporation of a linker such as EDTA or DTPA for the binding of copper (Figure 
1) interest could be focused on PET radiolabelling studies.15 Metal-complexed sulfonamides are particularly interesting as in 
some instances the binding affinity of the conjugate has been shown to exceed that of the parent sulfonamide due to the 
simultaneous binding of the sulfonamide to the catalytic zinc centre within the CA active site, and of the metal ion to a histidine 
residue critical to the catalytic cycle of CO2 processing.16,17,18   The compound fluorescein-thioureido-ethyl-sulphanilamide 
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(FTES) has already been shown to stain selectively cells which up-regulate the CA IX isozyme. In silico docking studies of the 
enzyme suggested that hydrogen bonding accounts for the increased affinity for CA IX over CA II with a guanidine residue 
specific to CA IX participating in hydrogen bonding with the carbonyl oxygen of the fluorescein tail of the inhibitor.8 Recently, 
the Florence group and collaborators also reported on the organometallic [(Cp-R)M(CO)3] (M=Re or 99m-Tc) arylsulfonamide 
conjugates which were found selective targeting of human Carbonic Anhydrase IX. 8c  This paper reports on the synthesis and 
characterisation of new conjugates of arylsulfonamides (grouped under three different ligand classes: thiosemicarbazonate-, 
amidothiolate- and porphyrin-based) and their corresponding metal complexes, i.e. complexes of technetium, rhenium, 
gallium, indium copper and zinc in their non-radioactive or radioactive form (for 64Cu and 99mTc). Cellular imaging tests were 
also performed on three (fluorescent) porphyrin ligands and one indium porphyrin complex, aiming to shed light into the cell 
inclusion of these conjugates and explore the effect of these sulfonamide derivatives on CA-mediated mechanisms. Their 
capacity to inhibit a series of carbonic anhydrase isozymes were performed via CA enzyme inhibition assays: the observed 
binding constants were used to assess potential candidates for use as SPECT or PET imaging agents for tumour hypoxia.  
Results and Discussion 
Arylsulfonamides conjugated with 64-copper(II) or zinc(II) bis(thiosemicarbazonate) complexes 
 
Figure 2: Schematic representations of of CuATSM and the new conjugates emerging from the H2ATSM/en precursor, H2L1, 
ZnL1 and CuL1 
The complex diacetyl-bis(N4-methylthiosemicarbazonato)copper(II),CuATSM, Figure 2 has been shown to be selective for 
hypoxic tissue in imaging studies, where the PET radioisotopes  60Cu, 61Cu or 64Cu were used,19,20,21 and, as such it has been 
used clinically for the detection of hypoxia in cancer.22,23 It has been shown24 that Cu(II) bis(thiosemicarbazonates) are stable 
in vitro in serum and can also be used to radiolabel bombesin at room temperature without compromising the biological 
targeting capabilities of the protein. Here, analogous bis(thiosemicarbazide) system was used to form new conjugates with 
arylsulfonamides (see Figure 3 and Experimental Section).  The possible impact on enzyme inhibition of the coordination of 
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zinc or copper to the bis(thiosemicarbazone) ligand conjugate was explored. Synthesis of the bis(thiosemicarbazone)-
sulfonamide H2L1 was accomplished in an 82% yield via the  carbodiimide-mediated coupling of 4-sulfamoylbenzoic acid with 
the previously described precursor H2ATSM/en.20 The complexes ZnL1 and CuL1 were produced in yields of 81% and 44% 
respectively by room temperature reaction of H2L1 in methanol solution with zinc(II) acetate and copper(II) acetate respectively. 
64CuL1 was prepared in excellent radiochemical incorporation (> 95%) by reaction of a DMSO solution of H2L1 with 64Cu(II) in 
aqueous acetate buffer. 
Arylsulfonamides conjugated to 99m-technetium(V) or ‘cold’ rhenium(V) complexes 
 
Figure 3: Schematic representations of new protected arylsulfonamide conjugated ligands and complexes with Re and 99mTc. 
In the case of Tc and Re we used the known MAG3, DADS and MAGpy ligands (see Figure 3) to study the effect of overall charge 
and ligand structures on CA enzyme inhibition. The MAG3 and DADS ligands have been used extensively with 99m-Tc and the 
complexes are rapidly and specifically excreted from the body via the kidneys25,26, a desirable attribute for radiotracers. The 
technetium(V) or rhenium(V) complexes of MAG3 and DADS share the same charge (-1) but have structural differences, while 
the neutral complex of MAGPy is different in both charge and structure.25,27 For the sulfonamide conjugates, high efficiency of 
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CAIX binding requires a favourable steric fit into the inhibitor binding site of the CAIX enzyme28  and secondary interactions 
such as H-bonding may be important. 
  In this study, three known ligands for Tc and Re (MAG3 , DADS and MAGPy), all bearing a pendant carboxylic acid group 
were synthesised and are reported. ABS (Figure 1) and  glycinated acetazolamide (Gly-AZA) containing a reactive amino group 
available for linking to a sulfonamide were first synthesised. These proligands  (H3L2Trt, H2L3Trt and H2L4Trt where Trt = trityl, 
Figures 3 and 4) were obtained via standard amide formation using a coupling agent (EDC or BOP, Experimental section). These 
conjugates were then successfully labelled with 99mTc as the Tc(V) mono-oxo dervatives.  Because technetium and rhenium are 
in the same group of the periodic table and share similar chemical and biological properties29, the bioassay results of the 
rhenium and technetium complexes are directly comparable. Therefore, due to the need to use a ‘cold’ HPLC confirmation 
method for the 99mTc complexes and to proceed to further studies on CAs inhibtion studies the isostructural rhenium complexes 
were also synthesised and fully characterised, as described in Experimental section.  
 
Figure 4: Schematic representations of the new protected acetazolamide conjugated ligands and complexes with Re(V) and 
99mTc(V) 
Arylsulfonamide conjugates with porphyrins and metalloporphyrins 
To explore if metalloporphyrins conjugated to sulfonamides would also target CAIX a range of porphyrins (Figure 5) conjugated 
to ABS or GlyAZA were synthesised together with their indium(III) and gallium(III) complexes. These were of interest as they 
provide the possibility of using the intrinsic fluorescence of the porphyrins to study cellular uptake mechanisms and tissue 
distributions in vivo. The peripheral porphyrin substituents were selected deliberately aiming to vary the overall charge and 
water solubility. The amide and sulfonamide monofunctionalised tetraarylporphyrin or tripyridylarylporphyrin ligands (H2L7 
through to H2L13) were synthesised from the carboxylate using standard coupling reactions with the appropriate amino 
sulfonamide. Whilst ABS is commercially available as the free amine, the structure of AZA is not suitable for direct amide 
coupling. Therefore, as shown briefly in Scheme 1, an amine functionalised sulfonamide was coupled via an amide linker to a 
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carboxyphenyl porphyrin precursor, using either the NHS activated ester or using BOP as a coupling agent with the porphyrin 
precursor of choice, which incorporates a carboxylate group.  To achieve a reliable nucleophilic amine source a Boc-glycine 
linker was introduced according to Scheme 1. Deprotection of the Boc group with TFA yielded a final functionalised AZA 
derivative suitable for coupling to the porphyrin scaffolds according to procedures described in Scheme 1, Experimental section 
and ESI. Figure 5 gives the schematic representation of the new free base porphyrin derivatives synthesised. 
 
 
Scheme 1: Schematic synthesis of derivatised acetazolamide for the aryl carboxylate-functionalised  porphyrin coupling:  
a) conc. HCl, EtOH, reflux 3 h; b) Boc-glycine, NEt3, iButyl chloroformate, MeCN, -10 °C to rt. 12 h; c) TFA, rt. 3 h. 
 
 
Figure 5: Structural representations of the free base porphyrin derivatives investigated. 
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Molecular structure of H2L9 by synchrotron X-ray diffraction 
Crystals of trisulfonated porphyrin H2L9 were grown by the slow infusion of acetone into an aqueous THF solution (1:1 v/v 
THF:water) of the compound. The crystals produced extremely weak but promising X-ray diffraction patterns only when a 
synchrotron X-ray source was used (SRS Daresbury, Station 9.8). The small crystal size (0.02 x0.02x0.35 mm), the large size of 
the unit cell and asymmetric unit, the weak scattering of the atoms involved and the extensive disorder of solvating water 
molecules made solving and refining this data set extremely challenging. The molecular structure is shown in Figure 6 (CCDC 
1028969). The sulfonamide bond lengths and angles are all in accordance with published X-ray crystal structures for aromatic 
sulfonamide structures30. Though the data set was extremely weak, a solution was found and the structure determination 
allowed the confirmation of the connectivity and thus the identity of this compound, in close agreement with 1H and 13C NMR, 
and ESI-MS data, and thus the formation of the desired functionalised porphyrin complex. The short amide C-N bond (C(45)-
N(5) 1.26 Å) found in H2L9 is again indicative of significant delocalization over the amide group, and extensive disorder in the 
sulfonamide arm necessitated modeling over several sites during refinement. Despite this, the overall conectivity is clear and 
shed light into the molecular strucuture of the first water solubile porphyrin-sulfonamide derivative. The crystal packing is 
described by a series of H-bonding interactions (Figure S1 in ESI) which network between solvent water molecules, sulfonate 
groups and sulfonamide amine groups, with H-bonding distances ranging between ca. 2.15 Å (between the sulfonamide amine 
nitrogen and water molecule) for (N(6)-O(13)) and ca. 2.77 Å (between a sulfonate oxygen and water molecule) for (O(8)-
O(14)). The intermolecular interactions observed include some weak aromatic interactions (with short range interactions of 
ca. 2.75 Å) whereby π-π stacking takes place via the T-shape stacking of phenyl rings on adjacent porphyrins (Figure S2 in ESI).  
 
 
 
 
 
 
 
 
Figure 6: Ball and stick representation of the molecular structure of H2L9 
CAIX Inhibition Assays 
Enzyme inhibition data was determined, for all those compounds which could be isolated in satisfactory yields and which 
showed aqueous solubility, for physiologically dominant hCA I and II and cancer-associated hCA IX and XII by assaying the CA 
catalysed hydration of CO231 and the data obtained is summarised in Table 1. The entry numbers 1-20 used in the following 
text refer to those listed in Table 1.  
Table 1: Enzyme inhibition studies (binding affinity data Ki (nM)) for sulfonamide series with calculated selectivity ratios.  
ABS = arenebenzylsulfonamide, AZA = actetazolamide, FTES = fluoresceinthioureidoethylsulfonamide. *Errors in the range of ± 5-10% of the 
reported value, from three different determinations. CAI and CAII are Human (cloned) isozymes. CAIX is the catalytic domain of the human, 
cloned isozyme. CAXII is the catalytic domain of the human recombinant isozyme, CO2 hydrase assay method. 
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 No Compound Ki  (nM) Selectivity ratios 
  CAI CAII CAIX CAXII CAI/CAIX CAII/CAIX CAXII/CAIX 
 1 H2L1 335 470 62 73 5.4 7.5 0.9 
 2 ZnL1 11.4 9.3 28 6.8 0.4 0.33 0.2 
         3 CuL1 33.1 9.0 9.0 6.1 3.6 1.0 0.7 
 4 [ReL2]- 432 1180 105 87 4.1 11.2 0.8 
 5 [ReL3]- 1030 1110 89 88 11.6 12.5 1.0 
 6 [ReL5]- 1020 1190 1270 85 0.8 0.9 0.1 
         7 H2L7 78 46 82 84 1.0 0.5 1.0 
 8 InClL7 91 111 87 80 1.0 15.1 1.0 
 9 H2L8 1080 818 54 46 20.0 15.2 1.0 
 10 GaClL8 442 841 38 71 11.6 22.1 1.9 
 11 InClL8 126 46 68 72 1.9 0.7 1.0 
 12 H2L9 2650 5750 435 720 6.1 13.2 1.7 
 13 InClL9 442 841 38 71 11.6 22.1 1.9 
 14 H2L10 451 770 49 66 9.2 15.7 1.3 
 15 H2L11 820 651 52 73 15.8 12.5 1.4 
 16 GaClL11 433 84 59 42 7.3 1.4 0.7 
 17 InClL11 391 39 86 35 4.6 1.0 1.0 
 18 H2L12 2970 3986 518 792 5.7 7.7 1.5 
 19 H2L13 655 520 39 45 16.8 13.3 1.1 
 20 InClL13 77 81 79 97 1.0 1.0 1.2 
 Control ABS 2100 160 33 3.2 63.6 4.9 0.1 
 Reference 
14b  
AZA 250 12 25 5.7 10 0.5 0.02 
 Control FTES 1300 45 24 - 54.2 1.9 - 
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In the cases of the bis(thiosemicarbazonates) studied (i.e. with Compound entries with No’s 1-3 in Table 2), the free 
ligand and the metal complexes all show low Ki values for CaIX and CaXII inhibition, that for the Cu complex being almost 
equivalent to ABS (given at the bottom of the table, and used as a control) itself. However, the discrimination between CaIX 
and the other isoforms is poor. The anionic Re complexes under entries 4-6 all appear to be active, and promising substrates 
to be used in this context however they show selectivity differences that are difficult to rationalise on the basis of structure or 
targeting group. The rhenium complex under entry 5 with a pendant sulfonamide has the best overall performance in this 
assay. Intriguingly, the free base porphyrin H2L7 and its corresponding indium complex,  which possess no sulfonamide 
functionality, both show reasonably strong binding affinities for the CA enzymes but in both cases show poor selectivity for CA 
IX and XII over both CA I and II. Introduction of the sulfonamide entities ABS (to give compound H2L8) increases the binding 
affinity for the CA IX and XII enzymes and dramatically increases the selectivity for these enzymes over the non-target CA I and 
II. In terms of CAIX inhibition with the porphyrins and metal complexes it is reassuring that the porphyrin derivative (see entry 
7 in Table 1) with no sulfonamide shows no selectivity for CAIX whereas the free base compound shown under entry 9 (having 
one aryl replaced by a pendant arylsulfonamide, H2L8) shows strong discrimination between CAIX and other isoforms and is 
one of the most effective compounds of those screened in this study. However the introduction of either indium   or gallium   
to give the metal complexes results in a loss in selectivity particularly with the indium complexes. Disappointingly, from the 
perspective of using these compounds for PET or SPECT imaging after incorporation of a metal-halide centre (e.g. In(III)-Cl or 
Ga(III)-Cl) and somewhat surprisingly, this generally appears to reduce the selectivity for CAIX over the other isoforms 
significantly. Free-base sulfonated porphyrin H2L9 (entry 12) and its corresponding In-Cl complex (entry 13) provide an 
exception to this with the In complex showing both stronger inhibition and higher selectivity. As with the metal complexes 
mentioned above there is no obvious correlation of the observed binding/selectivity characteristics with structure. It is likely 
that subtle factors involving secondary interactions within the binding pocket are dictating the overall inhibition patterns.  
Based on these results complexes under entries 5 and 13 are under current investigations in our laboratories, and are being 
taken forward for in vitro and in vivo studies using the 99mTc and 111In labelled variants respectively. For the AZA-derivatised 
metallo-porphyrin compounds (H2L11, H2L12 and H2L13) we observed a lower binding affinity to the CA XI and XII enzymes, whilst 
for the ABS metallo-porphyrin species we see an increased binding affinity for the CA XII enzyme. The shift from H2TPP to the 
pyridinium-functionalised porphyrin species results in a reduction in the selectivity for CA IX and XII over both CA I and II but 
the binding affinity to CA IX and CA XII is still favourable for both AZA- (H2L13) and ABS- (H2L10) functionalised species.  
Introduction of indium to the tetrapyrrole ring results in complete lack of selectivity towards CA IX and XII with a 
diminished binding affinity to both enzymes. This suggests that either the free base porphyrin provides additional non-covalent 
bonding interactions that enhance the overall binding affinity and selectivity towards the CA IX and CA XII enzymes or that the 
ubiquitous CA enzymes I and II provide additional interactions with the metallo porphyrins which enhance the binding 
interactions with these enzymes more so than with CA IX and CA XII. Shifting from H2TPP to the sulfonate species (H2L9) still 
shows a strong affinity for CA IX and XII over both CA I and II but the binding affinity for all the enzymes is dramatically reduced 
suggesting that the sulfonate groups act to inhibit binding, conversely introduction of the metal ion dramatically increases the 
binding affinity and selectivity for CA IX and XII over CA I and II. In general, all of the porphyrin species show a uniform medium 
strength binding affinity to CA IX and CA XII enzymes. All sulfonamide species show an enhanced selectivity for CA IX and CA 
XII over CA I and CA II in comparison to the porphyrin species alone indicating that the presence of the sulfonamide porphyrin 
conjugate has a positive effect towards improving selectivity. The selectivity ratios and binding affinities however are much 
poorer than the control sulfonamides ABS and AZA on their own and the fluorescein-thioureido-ethyl-sulphanilamide (FTES) 
ligand suggesting that the intrinsic affinity that the porphyrin group has for the CA enzymes prevents the sulfonamide groups 
from binding preferentially to the CA IX and CA XII enzyme isoforms. Several of the compounds do however show particularly 
favourable binding affinities such as the free base porphyrins H2L8 and the sulfonate variant H2L9.  
Docking studies, in line with those already reported by Supuran et al. will be carried out in future investigations to 
elucidate in full the structure activity relationships and the CA inhibition mechanism.8b 
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Confocal fluorescence imaging tests 
 
To assess the binding potential of the sulfonamide groups to the CA IX receptors, confocal fluorescence studies were performed 
with compounds H2L8, H2L9 and H2L10 on the HCT 116 colon carcinoma cell line. The HCT 116 line has been transfected to over-
express the CA IX enzyme (without the need for hypoxic culturing) and denoted CAIX positive. The empty-vector cell line, i.e. 
showing no expression of the CA IX enzyme, was denoted CAIX negative and was used as a control.  
Cells lines were cultured according to known protocols42 and as described below. Cells were seeded on to glass cover slips and 
left to adhere for 12 h overnight. Cells were incubated with free-base porphyrin compounds HL8, HL9, HL10 at 10 μM 
concentrations for 2 h at 37 oC. After 2 h, the cells were washed three times with PBS and confocal images recorded using a 
Zeiss LSM 510 META microscope, irradiating at 405 nm with emission collected above 565 nm. In each case a sample of 5 
images were recorded. Images shown in Figures 7 and 8 represent a fair sample of the recorded images. The two most notable 
observations are:  (a) the different porphyrin species investigated, whereby R = Ph (HL8), 4-O3SC6H4 (HL9) and MeNC5H4+ (HL10) 
show distinct cellular distributions; and (b) there is no distinguishable difference between the uptake in the positive CA IX 
expressing cell line and the empty vector cell line. Cellular imaging suggests that the uptake and localisation is strongly driven 
by the porphyrin unit and not by the sulfonamide groups. The H2TPP-type derivative H2L8 shows strong cytosol uptake with no 
nuclear staining.  
The sulfonate species H2L9 shows only very weak internalisation, as may be expected from the negative charge associated with 
the conjugate, whilst the pyridinium analogue H2L10 shows strong nuclear uptake in both cell lines. For compound H2L10, nuclear 
uptake was confirmed by colocalisation with the nuclear stain DAPI (as shown in Figure 9). The nuclear uptake of the pyridinium 
species mirrors the nuclear localisation observed by confocal fluorescence in the case of a positively charged 
tetra(methylquinolinium) porphyrin identified as a G-quadruplex interactive agent.43 In line with observations from the binding 
affinities measurements, it appears that the porphyrin unit dominate the cellular uptake of the conjugate. The porphyrin 
sulfonamides still had some affinity for the CA enzymes. However, the precise discrimination in terms of specific selectivity for 
the tumour expressing CA IX (and CA XII) enzyme(s) with respect to the other isoforms is not supported by this study. 
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Figure 7: Confocal fluorescence imaging: cellular uptake images of H2L8 (a) and (b); H2L9 (c) and (d); H2L10 (e) and (f) in HCT 
116 (CA IX positive, denoted HCT 116+ and CA IX negative denoted HCT 116−) cell lines. Typical bright-field images for the 
confocal fluorescence micrographs are provided in ESI†. Conditions are described in the text. 
 
Figure 8: Confocal fluorescence imaging showing the cellular uptake at 37 oC: a) H2L10 (λex = 405 nm, λem  > 565 nm); b) DAPI 
nuclear stain (λex = 405 nm, λem = 465-535 nm); c) overlay showing the simultaneous imaging with H2L10 and DAPI nuclear 
stain; d) overlay of H2L10, DAPI nuclear stain and brightfield image. Scalebar = micrograph width= 150 µm. 
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Radiolabelling tests for CAIX binding by the porphyrin 111In(Cl)L9 
Whilst the porphyrin species do not show the same favourable differentials between CA IX and XII over both CA I and II as the 
small sulfonamide groups on their own, the medium strength binding affinities and reasonable selectivity ratios are not 
discouraging for all of the derivatives. Of particular interest is the sulfonate derivative which when present as the metal 
complex InClL9 shows between 5-10 fold increased selectivity for CAIX over CA I and CAII. Whilst the H2TPP and pyridinium 
species show by confocal fluorescence rapid cellular uptake by a mechanism independent of CA IX expression, the sulfonate 
species displayed less cellular association. This is probably a result of the negative charge on the porphyrin. This may make it 
more suitable for CA binding in the same manner as the fluorescein derivative. FTES shows little cellular uptake as a result of 
its negatively charged free acid group but binds selectively to the membrane bound CA IX enzymes. The selectivity of the 
fluorescein derivative is only observed by confocal fluorescence after incubation for 24 h with a clear delineation of the cell 
membrane in CA IX expressing cells. As such uptake studies with the sulfonate compounds were repeated with 24 h incubation 
at 37 oC for H2L9 and InClL9. After 24 h it is observed that internalisation is now strongly evident with uniform uptake throughout 
the cytoplasm. No apparent difference between the HCT 116 CA IX positive and negative cell lines is observed. However it was 
noted that the cell lines after 24 h incubation showed clear signs of cell death, and uptake mechanisms independent of CA IX 
expression cannot be ruled out. Further studies will be required to measure the toxicity of these compounds. Incubation at 
concentrations orders of magnitude lower to reduce toxicity results in much weaker fluorescence and subsequently cellular 
uptake is not discernible from background autofluorescence. Whilst the porphyrins are fluorescent their quantum yields are 
still very weak (0.06 and 0.03 for H2L9 and its corresponding indium derivative InClL9, respectively) when compared to 
fluorescein (0.95) and so low concentrations (nanomolar range) of the compounds cannot be efficiently detected by 
fluorescence. To investigate further the porphyrins at lower concentrations radiolabelling studies have been performed.  
Compound H2L9 was radiolabelled using an adapted method with respect to previously published conditions42 with 111InCl3 and 
in vitro uptake studies carried out in the same two cell lines as used for confocal fluorescence tests. After 1, 3, 6 and 18 h 
incubation (37 oC) of compound H2L9 with both the CA IX positive and CA IX negative cell lines the cells were washed with PBS 
(to remove activity in the supernatant), 1M HCl (to remove activity associated with the cell membrane) and 1M NaOH (to lyse 
the cells of internalised activity) sequentially, and the supernatant, membrane associated activity and internalised associated 
activity isolated respectively and measured separately. Cell percentage uptake is given as the amount of activity internalised 
i.e. the activity in the 1 M NaOH wash with respect to the total activity and the amount of activity associated with the 
membrane i.e. the activity in the 1M HCl wash with respect to the total activity. The uptake data suggests low uptake in line 
with the fluorescence images.  Identical weak membrane associated activity is measured for both cell lines suggesting that no 
sulfonamide binding occurs in the CA IX positive cell line (Figure 9).  
Cell uptake is observed which may be mediated by sulfonamide binding but is more likely to arise from the intrinsic uptake of 
the porphyrin conjugate. A higher percentage of radioactivity is associated with the CA IX positive cell line, which might suggest 
some positive sulfonamide response, but there is potential for variation in the amount of protein in the different cell 
population, despite the same initial cell concentration. Detailed protein assays are beyond the scope of this work and were not 
completed so the difference in internalised activity as a result of difference in cell population cannot be immediately ignored. 
Comparable changes in cell uptake in both cell lines over the time course are observed for the total cell associated activity with 
a difference in associated activity over 18 h of only 1.5 %. This again suggests that there is no CA mediated mechanism of cell 
inclusion of these porphyrin conjugates.  
A closer inspection of the CA binding data (Table 1) suggested that the sulfonamide species InClL9 has an increased binding 
affinity of 5-10 fold in a CA IX expressing cell line based on binding affinities alone. This should lead to increased membrane 
and potentially increased internalised associated activity. On the basis of radiolabelling studies no such increase in uptake or 
binding is observed, which is in accord with the confocal fluorescent studies and suggests strongly that uptake and/or binding 
is not receptor-mediated via initial carbonic anhydrase recognition. Furthermore, the anionic sulfonamides show no apparent 
recognition for the CA IX receptors and the weak uptake is most probably driven by the intrinsic accumulation of the porphyrin 
entity. Given the rapid and strong cellular uptake of the cationic and neutral porphyrin species it was felt unlikely that they 
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would confer any better differential, with their cellular uptake dominated purely by the porphyrin entity and by a pathway 
independent of sulfonamide binding to CA IX enzymes. 
 
Figure 9: Uptake of [111-In]-labelled H2L9 species in HCT116 (CA IX positive) and HCT116 (CA IX negative) cell lines showing % 
activity associated with the cell membrane and internalised for each cell line. Experiments were carried out in triplicate and 
error bars indicate one standard deviation of the mean. 
Conclusions 
A range of new sulfonamide conjugated metal complexes involving bis(thiosemicarbazonate), amidothiolate and porphyrin 
ligands have been prepared with a view to developing PET and SPECT agents based on metallic radionuclides to target CAIX 
expression in vivo. These compounds were all fully characterised and successful, radiolabelling protocols resulting in a high 
radiochemical incorporation were established for the 64-Copper and 99m-Technetium complexes. Those complexes with 
solubility and stability in an aqueous environment suitable for the CA enzyme inhibition assay were screened for activity, by 
testing their ability to inhibit CAIX and other isoforms of the enzyme in vitro.  A series of sulfonamide porphyrin conjugates has 
been synthesised and fully characterised. Water soluble analogues have been developed for greater biocompatibility with no 
sign of acid hydrolysis of the amide bonds under sulfonating conditions and no sign of alkylation of the thiadiazole ring under 
methylating conditions.  A library of sulfonamide derivatives has been studied for their binding affinities to specific CA receptors 
to establish their affinity for the poor prognostic CA IX and CA XII enzymes. Our findings for the rhenium derivatives are 
comparable with those recently reported for organometallic [(Cp-R)M(CO)3] (M=Re or 99m-Tc) Arylsulfonamide conjugates 
investigated for the selective targeting of human Carbonic Anhydrase IX. 8c In general the porphyrin sulfonamide conjugates 
displayed positive selectivity for the CA IX and CA XII enzymes though metal insertion into the porphyrin resulted in loss of 
selectivity and reduced binding affinity. Conversely the sulfonate porphyrins showed the reverse effect showing improved 
binding and increased selectivity for CA IX and CA XII on indium complexation. Fluorescent studies in a CA IX positive and CA IX 
negative cell line indicate (after 2 h and 24 h incubation at 37 oC) that there is no obvious difference in the cellular binding or 
uptake between the two cell lines for the sulfonyl porphyrin species. A strong structural correlation with cellular uptake is 
observed with the neutral tetraphenyl porphyrins showing strong cytoplasm uptake, the cationic porphyrins showing nuclear 
accumulation whilst the sulfonyl porphyrins display only weak cell uptake. Radiolabelling studies with an indium(III)- labelled 
sulfonated ABS porphyrin identified identical weak membrane binding for the CA IX positive and CA IX negative cell lines and 
comparable cell internalisation suggesting that the conjugates cellular distribution and uptake was dominated by the porphyrin 
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core. Although these results showed no direct correlations between the structures and physical properties of the complexes 
and the observed activities, two compounds based on the porphyrin motif were identified as being good candidates to take 
forward to cellular and in vivo investigations. 
 
Experimental Procedures 
 
General: All reagents were purchased from Sigma-Aldrich, Merck Chemicals or Alfa-Aesar and were used as received unless 
otherwise stated. Na[99mTcO4] was obtained from a 99Mo/99mTc generator (GE Healthcare, UK). H2ATSM and H2ATSM/en were 
prepared according to published methods.32,33 ESI contains further details on HPLC and radioHPLC methods A-C used and 
intermediates’ syntheses.  
Diacetyl(N-4-methylthiosemicarbazone)(N-4-aminoethylamidophenyl-4-sulphamoylthiosemicarbazone),   H2L1, 
H2ATSM/en (150 mg, 0.51 mmol), 4-sulfamoylbenzoic acid (104 mg, 0.51 mmol), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (119 mg, 0.62 mmol) and hydroxybenzotriazole (84 mg, 0.62 mmol) were placed under N2 in 
a schlenk flask and DMF (5 ml) added. The yellow mixture was stirred for 18 h at room temperature and water (50 ml) added 
generating a yellow precipitate. This was collected by filtration, washed with water  and diethylether, and dried in vacuo to 
provide H2L (197 mg, 0.42 mmol, 82%).  
1H NMR (300 MHz, DMSO-d6)  ppm 10.34 (s, 1H, NHN=C), 10.24 (s, 1H, NHN=C), 8.88 (t, J = 5.3 Hz, 1H, CH2NHC=S), 8.60 (t, J = 
5.3 Hz, 1H, CH2NHC=O), 8.39 (q, J = 4.40 Hz, 1H, CH3NHC=S), 8.00 (d, J = 8.50 Hz, 2H, ArH), 7.89 (d, J = 8.50 Hz, 2H, ArH), 7.49 
(s, 2H, SO2NH2), 3.78 (td, J = 5.7, 5.3 Hz, 2H, CH2NHC=S), 3.54 (td, J = 5.7, 5.3 Hz, 2H, CH2NHC=O), 3.02 (d, J = 4.51 Hz, 2H, 
CH3NHC=S), 2.23 (s, 3H, CH3C=N), 2.21 (s, 3H, CH3C=N). 13C{1H} NMR (75.5 MHz, DMSO-d6)  ppm 178.5 (C=S), 178.1 (C=S), 165.9 
(C=O), 148.4 (C=N), 148.0 (C=N), 146.3 (Ar), 137.2 (Ar), 128.0 (Ar), 125.6 (Ar), 43.9 (CH2), 38.9 (CH2), 31.3 (CH3NH), 11.8 
(CH3C=N), 11.7 (CH3C=N). MS ES+: found 495.1, calc. for [M + Na]+ (C16H24N8NaO3S3) 495.1; ES-: found 471.1, calc. for [M – H]- 
(C16H23N8O3S3) 471.1. HPLC Rt = 10.86 min 
 Diacetyl(N-4-methylthiosemicarbazonato)(N-4-aminoethylamidophenyl-4-sulphamoylthiosemicarbazonato)zinc(II), ZnL1   
H2L1 (40 mg, 85 µmol) and Zn(OAc)2.2H2O (22 mg, 100 µmol) were stirred together in methanol (5 ml) at room temperature for 
2 h forming a bright yellow solution. Water (20 ml) was added and the solution evaporated to remove the methanol. The 
solution was extracted with ethyl acetate (3 x 10 ml) and the combined organic fractions dried (MgSO4), evaporated and dried 
under vacuum to give ZnL1 as a bright yellow solid (37 mg, 69 µmol, 81%).  
1H NMR (300 MHz, DMSO-d6)  ppm 8.72 (t, J = 4.5 Hz, 1H, CH2NHC=O),  7.97 (d, J = 8.5 Hz, 2H, ArH), 7.88 (d, J = 8.5 Hz, 2H, 
ArH), 7.49 (s, 2H, SO2NH2), 3.51-3.44 (m, 2H, CH2), other CH2 obscured by water peak, 3.16 (d, J = 5.0 Hz, 2H, CH3NHC=S), 2.20 
(s, 3H, CH3C=N), 2.18 (s, 3H, CH3C=N). HRMS ES+: found 535.0320, calc. for [M + H]+ (C16H23N8O3S3Zn) 535.0347. HPLC Rt = 10.12 
min 
Diacetyl(N-4-methylthiosemicarbazonato)(N-4-aminoethylamidophenyl-4-sulphamoylthiosemicarbazonato)copper(II), 
CuL1   
H2L1 (40 mg, 85 µmol) and Cu(OAc)2.2H2O (22 mg, 100 µmol) were stirred together in methanol (5 ml) at room temperature for 
2 h forming a brown solution. Water (20 ml) was added and the solution evaporated to 1/3 volume to produce CuL as a brown 
precipitate, which was collected by filtration and dried under vacuum (20 mg, 38 µmol, 44 %). HRMS ESI+: found 534.0364, calc. 
for [M + H]+ (C16H23N8O3S3Cu) 534.0351. HPLC Rt =  11.98 min. 
Syntheses of technetium and rhenium conjugates 
N-(2-oxo-2-((2-oxo-2-((4-sulfamoylphenylethyl)amino)ethyl)amino)ethyl)-2-(tritylthio)acetamide TrtMAG3-ABS, TrtH3L2 
Succinimido-2-((triphenylmethyl)thio)acetate (1) was prepared following literature procedures34, 3. To a solution of (1) (3.44 g, 
7.98 mmol) in 1,2-dimethoxyethane (35 mL) and DMF (18 mL) was added a solution of triglycine (1.52, 8.04 mmol) and NaHCO3 
(1.38 g) in water (18 mL). The resulting solution was stirred at RT for 3 h and then concentrated in vacuo to remove 1,2-
dimethoxyethane. Dilution with water (35 mL) and treatment with 50% aqueous citric acid (6 mL) gave a white solid of Trt-
MAG3 (2), which was recrystallized in ethanol (2.90 g, 71.9 %).  
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To a solution of (2) (393 mg, 0.777 mmol) in DMF (5 mL) was added ABS (155 mg, 0.774 mmol), EDC (149 mg, 0.777 mmol), 
HOBT (104 mg, 0.770 mmol) and TEA (24 µL). The reaction was left in ice bath for 1 h and then at RT for 1 day. The solvent was 
evaporated thereafter. The residue was re-dissolved in ethyl acetate (10 mL) and washed with 10% citric acid, 3% NaHCO3 and 
saturated brine, 20 mL each. The solids, which precipitated when washed with NaHCO3 and saturated brine, were collected. 
The organic solution was collected and dried under vacuum. The solutions of the raw product were combined and recrystallized 
from ethanol/water to give TrtH3L2 (440 mg, 82.6%).  
1H NMR (d6-DMSO, δ, 300 MHz):2.75 (t, J=7.2Hz, 2H), 2.84 (s, 2H), 3.25 (m, 2H), 3.61 (m, 4H), 3.68 (d, J=4.9Hz, 2H), 7.21-7.37 
(m, 17H), 7.71 (d, J=8.3Hz, 2H), 7.92 (t, J=5.3Hz, 1H), 8.12 (t, J=5.7Hz, 1H), 8.22-8.25 (m, 2H). 13C NMR (d6-DMSO, δ, 75 MHz): 
35.2, 36.4, 42.5, 42.6, 42.8, 42.8, 66.4, 126.1, 127.3, 128.5, 129.5, 129.5, 142.5, 144.0, 144.4, 168.2, 169.1, 169.5, 169.6. 
ES/MS(+): m/z=688.2915 (Calc. m/z=688.2264) [M+H]+. HPLC (Method B): Rt=11.88 min.   
N,N’-(3-oxo-3-((4-sulfamoylphenylethyl)amino)propane-1,2-diyl)bis(2-(tritylthio)acetamide, TrtDADS-ABS,  H3L3Trt 
Ethyl 2,3-bis(triphenylmethylthioacetylamino)propanoate (3) was prepared following the literature procedure35. To 3 (1.05 g, 
1.33 mmol) in a 1:1 mixture of THF and water (80 mL), NaOH (100 mg, 2.5 mmol) was added. The mixture was heated to reflux 
for 3 h under N2. The mixture was adjusted to pH=2 by addition of 6 M HCl and was concentrated to 30 mL under reduced 
pressure. The precipitate that formed was collected by filtration and dried under vacuum to give Trt-DADS (4) (825 mg, 84.2%). 
To a solution of 4 (147 mg, 0.199 mmol) in DMF (5 mL) was added ABS (40.0 mg, 0.200 mmol), EDC (37.8 mg, 0.200 mmol), 
HOBT (26.7 mg, 0.198 mmol) and TEA (6 µL). The reaction was left in ice bath for 1 h and then at RT overnight. The solvent was 
evaporated and the residue re-dissolved in ethyl acetate (20 mL). The solution was washed with 10% citric acid, 3% NaHCO3 
and saturated brine, 20 mL each. The organic layer was collected and dried under vacuum. The raw product was combined and 
recrystallized from ethanol/water to give TrtH3L3 (108 mg, 59.0%).  
1H NMR (d6-DMSO, δ, 300 MHz): 2.70 (m, 2H), 2.74 (s, 2H), 2.80 (s, 2H), 3.11 (m, 2H), 3.21 (m, 2H), 4.11 (m, 1H), 7.19-7.34 (m, 
32H), 7.71 (d, J=8.4Hz, 2H), 7.86 (t, J=5.7Hz, 1H), 8.00-8.07 (m, 2H). 13C NMR (d6-DMSO, δ, 75 MHz): 35.2, 36.4, 36.5, 40.4, 41.1, 
53.3, 66.3, 126.1, 127.2, 128.5, 129.5, 142.5, 144.0, 144.4, 144.5, 167.8, 168.1, 169.6. ES/MS(+): m/z=941.541 (Calc. 
m/z=941.284) [M+Na]+. HPLC (Method B in ESI): Rt=15.37 min.  
N’-(pyridine-2-ylmethyl)-N5-(4-sulfamoylphenylethyl)-2-(2-tritylthio)acetamido)pentanediamide, TrtMAGpy-ABS, H2L4Trt 
Trt-MAGpy (5) was synthesized following the literature procedure36. Compound 5 (111 mg, 0.200 mmol) was added to DMF (5 
mL) and mixed with ABS (40.0 mg, 0.200 mmol), EDC (37.8 mg, 0.200 mmol), HOBT (26.7 mg, 0.198 mmol) and TEA (6 µL). The 
reaction was left at RT for 1 day. The solvent was evaporated and the residue was washed with 0.1 M HCl (3×10 mL) and ethyl 
acetate (2×10 mL). The solid was dried under vacuum to give H2L4Trt (37.8 mg, 25.7%).  
1H NMR (d6-DMSO, δ, 300 MHz): 1.77 (m, 2H), 1.96 (t, J=7.7Hz, 2H), 2.65 (t, J=6.8Hz, 2H), 2.76 (s, 2H), 3.14 (td, JA=6.6Hz, 
JB=19.3Hz, 2H), 4.09 (td, JA=5.4Hz, JB=7.8Hz, 1H), 4.24 (d, J=5.7Hz, 2H), 7.08-7.33 (m, 18H), 7.63 (d,  J=8.0Hz, 2H) Ar-H; 7.86 (t, 
J=5.5Hz, 1H), 8.13 (d, J=7.6Hz, 1H), 8.36 (d, J=3.9Hz, 1H), 8.41 (t, J=5.7Hz, 1H). 13C NMR (d6-DMSO, δ, 75 MHz): 26.9, 31.5, 34.8, 
35.7, 40.0, 41.8, 53.6, 66.9, 123.9, 124.3, 125.9, 126.7, 127.7, 129.1, 129.3, 141.6, 143.2, 143.8, 143.9, 144.1, 155.3, 170.2, 
172.8, 173.2.  ES/MS(+): m/z=736.2386 (Calc. m/z=736.2628) [M+H]+. HPLC (Method A): Rt=12.04 min.   
N-(2-oxo-2-((2-oxo-2-((2-oxo-2-((2-oxo-2-((5-sulfamoyl-1,3,4-thiadiazol-
2yl)amino)ethyl)amino)ethyl)amino)ethyl)amino)ethyl)-2-(tritylthio)acetamide, TrtMAG3-glyAZA, H3L5Trt 
Trt-MAG3 (2) (50.5 mg, 0.100 mmol) was added to DMF (5 mL) and mixed with glyAZA (35.1 mg, 0.100 mmol), EDC (20.0 mg, 
0.105 mmol), HOBT (13.5 mg, 0.100 mmol) and TEA (20 µL). The reaction was left in ice bath for 1 h and then at RT for 1 day. 
The solvent was evaporated and the residue was re-dissolved in ethyl acetate (10 mL). The solution was washed with 1 M HCl, 
3% NaHCO3 and saturated brine, 20 mL each. The organic solution was collected and dried under vacuum. The raw product 
was recrystallized from ethanol/water to give H3L5Trt (41.0 mg, 56.6%).  
1H NMR (d6-DMSO, δ, 300 MHz): 2.84 (s, 2H), 3.63 (d, J=5.6Hz, 2H), 3.71 (d, J=5.0Hz, 2H), 3.77 (d, J=5.9Hz, 2H), 4.08 (d, J=5.5Hz, 
2H), 7.24-7.34 (m, 15H), 8.11-8.19 (m, 4H), 8.35 (s, 2H), 13.11 (s, 1H). 13C NMR (d6-DMSO, δ, 75 MHz): 36.3, 42.2, 42.4, 42.7, 
66.4, 127.3, 128.5, 129.5, 144.5, 161.5, 164.9, 168.2, 169.4, 169.6, 170.0, 171.5. ES/MS(-): m/z=723.1169 (Calc. m/z=723.1478) 
[M-H]-. HPLC (Method A): Rt=9.88 min.   
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N5-(2-oxo-2-((5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino)ethyl)-N1-(pyridine-2-ylmethyl)-2-(2-
(tritylthio)acetamido)pentanediamide, TrtMAGpy-glyAZA or H2L6trt. 
Trt-MAGPy (5) (79.7 mg, 0.144 mmol) was mixed with BOP (76.4 mg, 0.173 mmol) and DIPEA (90 µL, 0.52 mmol) in DMF (5 mL) 
in ice bath for 20 min., then glyAZA  (synthesised as above, (c) (60.7 mg, 0.173 mmol) was added. The mixture was stirred at 
RT overnight. The solvent was evaporated, and 3M HCl (20 mL) and ethyl acetate (20 mL) were used consecutively to wash off 
the impurities. The solid was further purified by silica gel chromatography using DCM/MeOH (9/1 by volume) to give H2L6Trt 
(32.3 mg, 29.0%).  
1H NMR (d4-CD3OD, δ, 500 MHz): 1.87-2.15 (m, 2H), 2.29-2.42 (m, 2H), 3.08 (d, J=1.26 Hz, 2H), 4.15-4.25 (m, 2H), 4.27 (dd, 
JA=7.88, JB=5.99 Hz, 1H), 4.53 (s, 2H), 4.61 (br, 2H), 7.09 - 7.52 (m, 17H), 7.80 (td, JA=7.72, JB=1.58 Hz, 1H), 8.48 (d, J=4.41 Hz, 
1H). 13C NMR (d4-CD3OD, δ, 125 MHz): 28.7, 32.6, 37.2, 43.6, 45.4, 54.7, 68.5, 123.0, 123.9, 128.2, 129.2, 130.8, 139.0, 145.6, 
149.7, 158.9, 163.3, 166.6, 170.7, 171.4, 173.6, 175.7. ES/MS(+): m/z=795.1804 (Calc. m/z=795.1812) [M+Na]+. HPLC (Method 
A): Rt=12.04 min.  
Syntheses of rhenium complexes. 
Sodium  N-(2-oxo-2-((2-oxo-2-((4-sulfamoylphenylethyl)amido)ethyl)amido)ethyl)-2-thioacetamido-oxorhenium(V), 
Na[ReOMAG3-ABS],  Na[ReOL2] 
Trt-MAG3 (5) (240 mg, 0.474 mmol) and sodium acetate (258 mg, 3.14 mmol) were mixed in dry methanol (60 mL), followed 
by addition of precursor [ReOCl3(PPh3)2] (395 mg, 0.474 mmol). After being refluxed for 4 h, the solution turned orange. After 
cooling, the solution was filtered and evaporated to dryness. The residue was chromatographed on silica gel with 
DCM/methanol. The orange eluent was collected and dried to give Na[ReO-MAG3] (6) (185 mg, 80.6%). After 6 (48.4 mg, 0.100 
mmol) was dissolved in phosphate buffer (10 mL, 0.1 M, pH=6.0), ABS (20.0 mg, 0.100 mmol) in acetonitrile (1 mL) was added 
to the solution, followed by EDC (19.1 mg, 0.100 mmol) and TEA (14 μL). The mixture was stirred at RT overnight. After the 
solvent was evaporated, the residue was chromatographed on silica gel with DCM/methanol (3/1 by volume). The orange 
eluent was collected and dried to give Na[ReOMAG3-ABS] (37.1 mg, 55.6%). 
 1H NMR (d4-CD3OD, δ, 500 MHz): 2.79-2.91(m, 2H), 3.41 (t, J=7.3Hz, 2H), 3.78 (d, J=17.2Hz, 1H), 4.02 (d, J=17.3Hz, 1H), 4.26 (d, 
J=18.0Hz, 1H), 4.28 (d, J=18.1Hz, 1H), 4.40 (d, J=18.0Hz, 1H), 4.65 (d, J=16.6Hz, 1H), 4.74 (d, J=18.2Hz, 1H), 4.99 (d, J=16.6Hz, 
1H), 7.39 (d, J=8.3, 2H), 7.82 (d, J=8.2, 2H), 13C NMR (d4-CD3OD, δ, 125 MHz): 34.3, 41.1, 41.5, 43.5, 49.9, 54.5, 57.7, 127.8, 
130.5, 142.7, 144.0, 191.4, 194.7, 195.8. ES/MS(-): m/z=644.0281 (Calc. m/z=643.9832) [M]-. IR: 978 cm-1 (Re=O), 1616 cm-
1(C=O). UV-Vis: λabs(MeOH)/nm (ε/ M-1·cm-1)=224 (2.52×104), 274 (sh, 5.73×103), 339 (sh, 3.23×102), 402 (1.27×102), 485 (22). 
HPLC (Method C): Rt=3.03 min.  
N,N’-(3-oxo-3-((4-sulfamoylphenylethyl)amido)propane-1,2-diyl)bis(2-thioacetamido)oxorhenium(V) Na[ReODADS-ABS], 
or Na[ReOL3]  
Na[ReODADS] (7) was synthesized from (4) according to the method described for Na[ReOMAG3] (6); (50.1 mg, 70.5%). The 
title compound was synthesized by coupling 7 with ABS using the same method as described above for the MAG3 system  (35.8 
mg, 51.5%). 1H NMR (d4-CD3OD, δ, 500 MHz): 3.03 (m, 2H), 3.20 (t, J=7.4, 2H), 3.78 (d, J=17.4Hz, 1H), 3.84 (d, J=17.1 Hz, 1H), 
4.14 (d, J=17.4Hz, 1H), 4.43 (d, J=16.9Hz, 1H), 4.75 (d, J=8.4Hz, 1H), 5.00 (d, J=12.9Hz, 1H), 7.50 (d, J=8.6, 2H), 7.91 (d, J=8.5, 
2H), (N.B.: the 1H resonance of the other NCH2CHN proton was overlapped with other peaks). 13C NMR (d4-CD3OD, δ, 125 MHz): 
32.8, 40.1, 42.9, 43.5, 59.2, 69.6, 126.3, 129.1, 141.3, 142.4, 194.2, 195.8, 196.4. ES/MS(-): m/z=632.9900 (Calc. m/z=632.9941) 
[M]-. IR: 962 cm-1(Re=O), 1581 cm-1(C=O). UV-Vis: λabs(MeOH)/nm (ε/ M-1·cm-1)=226 (2.93×104), 249 (sh, 1.10×104), 300 (sh, 
3.15×103), 332 (sh, 1.58×103), 402 (1.83×102), 489 (11). HPLC (Method 3): Rt=4.27 min.  
N-(2-oxo-2-((2-oxo-2-((2-oxo-2-((2-oxo-2-((5-sulfamoyl-1,3,4-thiadiazol-
2yl)amido)ethyl)amido)ethyl)amido)ethyl)amido)ethyl)-2-(thio)acetamido Na[ReOMAG3-glyAZA] or Na[ReOL5] 
The title compound was synthesized by coupling 6 with glyAZA using an analogous method to that described for the synthesis 
of  (45.1 mg, 64.1%). 1H NMR (d4-CD3OD, δ, 500 MHz): 2.91 (d, J=6.9, 2H), 3.82 (d, J=17.2Hz, 1H), 4.05 (d, J=17.2Hz, 1H), 4.29 
(d, J=18.6 Hz, 1H), 4.32 (d, J=18.8Hz, 1H), 4.42 (d, J=18.2Hz, 1H), 4.73 (d, J=17.1Hz, 1H), 4.79 (d, J=18.1Hz, 1H), 5.05 (d, J=17.1Hz, 
1H). 13C NMR (d4-CD3OD, δ, 125 MHz): δ(ppm)=41.1, 43.6, 54.5, 56.1, 57.7, 164.61, 191.5, 194.7, 195.8. ES/MS(-): m/z=680.9280 
(Calc. m/z=680.9650) [M]-. IR: 977 cm-1(Re=O), 1629 cm-1(C=O). UV-Vis: λabs(MeOH)/nm (ε/ M-1·cm-1)=221 (1.43×104), 270 (sh, 
4.61×103), 337 (sh, 3.18×102), 397 (1.03×102), 491 (18). HPLC (Method A): Rt=6.62 min.  
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5-[4-(N-propyl benzamide)]-10,15,20-tri(4-pyridyl)-porphyrin, [TPyP-propyl, H2L7] 
4-(10,15,20-Triphenylporphyrin-5-yl)-benzoic acid37 and 5-(4-Carboxyphenyl)-10,15,20-tris(4-pyridyl)porphyrin 38, were 
synthesised according to literature methods with analytical data in accord with the literature values (ESI). 
5-[4-(N-propyl benzamide)]-10,15,20-tri(4-pyridyl)-porphyrin was synthesised employing general amide coupling method B 
(ESI). 5-(4-Carboxyphenyl)-10,15,20-tris(4-pyridyl)porphyrin 9 (75 mg, 0.113 mmol), DIPEA (38.7 mg, 52.3 μL 0.300 mmol), 
propylamine (7.97 mg, 8.04 μL, 0.135 mmol), BOP (67.5 mg, 0.146 mmol), CHCl3 (10 mL). 5-[4-(N-propyl benzamide)]-10,15,20-
tri(4-pyridyl)-porphyrin was purified via silica gel chromatography (0 % to 5 % MeOH in CHCl3). Yield: 65.2 mg, 0.093 mmol, 82 
%. 
1H NMR (300 MHz, d6 –DMSO, 25 ºC):  9.40 (d, 6H, J = 6.1, CHpy), 9.14 (m, 8H, CHpyrr), 8.91 (m, 6H, CHpy), 8.65 (t, 1H, J = 5.5, 
CONH), 8.27 (d, 2H, J = 7.9, ArH), 8.15 (d, 2H, J = 8.1, ArH), 3.52 (m, 2H, CONHCH2CH2CH3), 1.81 (m, 2H, CONHCH2CH2CH3), 1.07 
(t, 2H, J = 6.9, CONHCH2CH2CH3), -2.95 (br s, 2H, ring NH). ESI-MS calcd for C44H35N8O [M + H]+ 703.2928, found 703.2935 
5-[4-(N-propyl benzamide)]-10,15,20-tri(4-pyridyl)-porphyrinchloroindium(III), InClL7 
This was prepared using general metal complexation method 1. H2L7 (50.0 mg, 0.072 mmol, NaOAc (35.0 mg, 0.429 mmol, InCl3 
(32.0 mg, 0.143 mmol), HOAc (10 ml). Yield: 51.2 mg, 0.061 mmol, 84%  
1H NMR: (300 MHz, d6-DMSO, 25oC): 8.99 (s, 8H, CHpyr), 8.50 (t, 1H, J = 5.4, CONH), 8.31 (2xd, 2x2H, ArH), 8.22 (m, 6H, o-Ph), 
7.85 (m, 9H, o,m,p-Ph), 3.43 (m, 2H, CONHCH2CH2CH3), 1.75 (m, 2H, CONHCH2CH2CH3), 1.02 (t, 3H, CONHCH2CH2CH3). ESI-MS 
Calculated for C48H36InN5O [M – Cl]+, 812.1875, found 812.1855; HPLC: (method A in ESI): Rt = 10.64 min.  
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-triphenylporphyrin, [H2TPP-ABS], H2L8 
The title compound was synthesised employing general peptide coupling method 1. 8 (250 mg, 0.331 mmol), 4-(2-
aminoethyl)benzenesulfonamide (100 mg, 0.500 mmol), DIPEA (64.6 mg, 87.1 μL, 0.500 mmol), DMF (10 mL).  Purification was 
achieved by  silica gel chromatography (5 % MeOH in CHCl3). Yield: 236 mg, 0.281 mmol, 85 %. 
1H NMR (300 MHz, d6 –DMSO, 25 ºC):  8.99 (t, 1H, J = 5.5, CONH), 8.81 (m, 8H, CHpyrr), 8.29 (d, 2H, J = 8.1, ArH), 8.23 (d, 2H, 
J = 8.4, ArH), 8.17 (m, 6H, o-ArH), 7.84 (d, 2H, J = 8.4, ArH), 7.77 (m, 9H, m,p-ArH), 7.55 (d, 2H, J = 8.4 ArH), 7.37 (s, 2H, SO2NH2), 
3.69 (m, 2H, CONHCH2CH2), 3.06 (t, 1H, J = 7.2, CONHCH2CH2). 13C NMR (125 MHz, d6 –DMSO, 25 ºC):  166.3, 144.0, 143.9, 
142.2, 141.2, 134.2, 134.1, 131.0 (bs), 129.3, 128.1, 127.0, 125.9, 120.3, 120.2, 119.1, 34.9, 25.3. Mass Spectrum ESI-MS calcd 
for C53H40N6O3S [M + H]+ 841.2961, found 841.2768. HPLC: (Method A) Rt = 11.81 min. Elem. Anal.: Found: C; 75.2 %, H; 4.9 %, 
N; 10.1 %. Calc.: C; 75.7 %, H; 4.8 %, N; 10.0 %.  
5-[4-(N-(2-Oxo-2-(5-sulphamoyl-1,3,4-thiadiazol-2-ylamino)ethyl)benzamide)]-10,15,20-triphenyl-porphyrin, [H2TPP-AZA], 
H2L11 
The title compound was synthesised employing general amide coupling method 1. 8 (330 mg, 0.436 mmol), glyAZA (180 mg, 
0.512 mmol), DIPEA (66.2 mg, 89.2 μL, 0.512 mmol), DMF (10 mL).  Purification was achieved via silica gel chromatography (2 
to 8 % MeOH in CHCl3). Yield: 256 mg, 0.292 mmol, 67 %. 
1H NMR (500 MHz, d6 –DMSO, 25 ºC):  13.39 (s, 1H, CONH-thiadiazole ), 9.44 (t, 1H, J = 5.5, CONH), 8.84 (m, 8H, CHpyrr), 8.40 
(s, 2H, SO2NH2), 8.37 (m, 4H, ArH), 8.23 (m, 6H, o-ArH), 7.84 (m, 9H, m,p-ArH), 4.45 (d, 2H, J = 5.6, CONHCH2CONH), -2.90 (s, 
2H, ring NH). 13C NMR (125 MHz, d6 –DMSO, 25 ºC):  169.6, 166.8, 164.5, 161.3, 144.5, 141.1, 134.2, 134.2, 133.0, 131.5, 128.1, 
127.0, 126.1, 120.3, 120.1, 118.9, 43.0. ESI-MS calcd for C49H36N9O4S2 [M + H]+ 878.2326, found 878.2275. HPLC: (Method A) Rt 
= 10.82 min. Elem. Anal.: Found: C; 66.8 %, H; 3.8 %, N; 14.4 %. Calc.: C; 67.0 %, H; 4.0 %, N; 14.4 %.  
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-triphenylporphyrin(chloroindium(III)), [In(Cl)TPP-ABS] or [InClL8] 
The title compound was synthesised employing general metal complexation method 1. H2L8 (74.5 mg, 0.087 mmol), NaOAc 
(43.6 mg, 0.532 mmol), InCl3 (39.2 mg, 0.177 mmol), AcOH (10 mL). A maroon coloured solid was obtained. Yield: 69.7 mg, 
0.070 mmol, 81 %. 
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1H NMR (300 MHz, d6 –DMSO, 25 ºC ):  9.11 (t, 1H, J = 5.6, CONH), 9.13-9.01 (m, 8H, CHpyrr),  8.26  (d, 2H, J = 7.8, ArH),  8.19 
(m, 8H, o-Ph, ArH), 7.95 (d, 2H, J = 8.2, ArH), 7.89 (m, 9H, m,p-Ph), 7.51 (d, 2H, J = 8.0, ArH),  3.71 (m, 2H, CONHCH2CH2), 3.04 
(t, 2H, J = 7.6, CONHCH2CH2). 13C NMR (75.5 MHz, d6 –DMSO, 25 ºC):  166.1, 148.0, 147.8, 147.7, 147.4, 144.5 144.1, 141.9, 
141.3, 134.4, 134.2, 133.9, 132.54, 132.51, 132.4, 130.5, 128.1, 127.1, 125.9, 125.8, 121.5, 121.3, 120.1, 38.2. 27.4. ESI-MS 
calcd for C53H38InN6O3S [M - Cl]+ 953.1765, found 953.1789.  HPLC: (Method A) Rt = 10.12 min. Elem. Anal.: Found: C; 63.9 %, H; 
4.0 %, N; 8.7 %. Calc.: C; 64.4 %, H; 3.9 %, N; 8.5 %. 
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-triphenylporphyrin(chlorogallium(III)), [Ga(Cl)TPP-ABS] or [GaClL8]  
The title compound was synthesised employing general metal complexation method 1. H2L8 (68.5 mg, 0.082 mmol), NaOAc 
(40.1 mg, 0.489 mmol), GaCl3 (28.7 mg, 0.163 mmol), AcOH (10 mL). A maroon coloured solid was obtained. Yield: 57.3 mg, 
0.061 mmol, 74 %. 
1H NMR (500 MHz, d6 –DMSO, 25 ºC):  8.92 (m, 8H, CHpyrr), 8.76 (t, 1H, J = 5.5, CONH), 8.32 (d, 2H, J = 7.6, ArH), 8.21 (d, 2H, J 
= 7.7, ArH), 8.26 (m, 6H, o-Ph), 7.88 (d, 2H, J = 8.1, ArH), 7.85 (m, 9H, m,p-Ph), 7.49 (d, 2H, J = 7.9, ArH),  3.75 (m, 2H, 
CONHCH2CH2), 3.15 (t, 2H, J = 7.3, CONHCH2CH2). ESI-MS calcd for C53H38GaN6O3S [M - Cl]+ 907.1982, found 907.1965. HPLC: 
(Method A) Rt = 10.05 min. Elem. Anal.: Found: C; 67.8 %, H; 4.3 %, N; 8.7 %. Calc.: C; 67.5 %, H; 4.1 %, N; 8.9 %. 
5-[4-(N-(2-Oxo-2-(5-sulphamoyl-1,3,4-thiadiazol-2-ylamino)ethyl)benzamide)]-10,15,20-triphenyl-
porphyrin(chloroindium(III)), [In(Cl)TPP-AZA] or [InClL11] 
The title compound was synthesised employing general metal complexation method 1 (ESI). H2L11 (40.0 mg, 0.046 mmol), 
NaOAc (22.0 mg, 0.273 mmol), InCl3 (19.7 mg, 0.091 mmol), AcOH (10 mL). A purple coloured solid was obtained. Yield: 34.0 
mg, 0.033 mmol, 72 %. 
1H NMR (500 MHz, d6 –DMSO, 25 ºC):  9.06 - 9.03 (m, 2H, CHpyrr), 8.99 (m, 7H, CHpyrr, CONH), 8.43 (d, 2H, J = 8.1, ArH), 8.36 (d, 
2H, J = 8.3, ArH), 8.25 (m, 6H, o-ArH), 7.90 (m, 9H, m-,p-ArH), 4.20 (d, 2H, J = 5.9, CONHCH2). 13C NMR (125 MHz, d6 –DMSO, 25 
ºC):  175.8, 175.0, 172.1, 165.9, 148.12, 148.09, 148.06, 147.8, 144.1, 141.4, 134.5, 134.4, 134.2, 132.6, 132.5, 132.5, 128.2, 
127.0, 125.9, 121.4, 121.3, 120.3, 45.5. Mass Spectrum ESI-MS calcd for C49H33InN9O4S2 [M - Cl]+ 990.1130, found 990.1090. 
HPLC: (Method A) Rt = 9.99 min. 
5-[4-(N-(2-Oxo-2-(5-sulphamoyl-1,3,4-thiadiazol-2-ylamino)ethyl)benzamide)]-10,15,20-triphenyl-
porphyrin(chlorogallium(III)), [Ga(Cl)TPP-AZA] or [GaClL11] 
The title compound was synthesised employing general metal complexation method 1. H2L11 (50.0 mg, 0.057 mmol), NaOAc 
(28.0 mg, 0.341 mmol), GaCl3 (21.0 mg, 0.114 mmol), AcOH (10 mL). A maroon coloured solid was obtained. Yield: 45.3 mg, 
0.046 mmol, 81 %. 
1H NMR (500 MHz, d6 –DMSO, 25 ºC):  9.13-8.91 (m, 8H, CHpyrr), 8.76 (br s, 1H, CONH), 8.40 (d, 2H, J = 7.3, ArH), 8.31 (d, 2H, J 
= 7.5, ArH), 8.22 (m, 6H, o-ArH), 7.86 (m, 9H, m-p-ArH), 4.20 (d, 2H, J = 4.9, CONHCH2). 13C NMR (75.5 MHz, d6 –DMSO, 25 ºC): 
 165.9, 147.3, 147.0, 143.6, 140.8, 134.2, 132.3, 132.2, 128.4, 127.2, 126.1, 120.4, 119.4, 45.1.   ESI-MS calcd for 
C49H33GaN9O4S2 [M - Cl]+ 944.1347, found 944.1334. HPLC: (Method A) Rt = 10.11 min. Elem. Anal.: Found: C; 60.5 %, H; 3.6 %, 
N; 12.2 %. Calc.: C; 60.0 %, H; 3.4 %, N; 12.8 %. 
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-tri(4-sulfonylphenyl)porphyrin, [H2TSPP-ABS], H2L9 
The title compound was synthesised employing the general sulfonation method (ESI). H2L7 (70.0 mg, 0.083 mmol), conc. H2SO4 
(2 mL). Yield : 66.6 mg, 0.058 mmol, 70 %. 
1H NMR (500 MHz, d6 –DMSO, 25 ºC):  9.05 (t, 1H, J = 5.7, CONH), 8.82 (m, 8H, CHpyrr), 8.29 (d, 2H, J = 8.0, ArH), 8.21 (m, 6H, 
ArHSO3Na), 8.17 (d, 2H, J = 8.1 Hz, ArH), 8.05 (m, 6H, ArHSO3Na), 7.87 (d, 2H, J = 8.1, ArH), 7.61 (d, 2H, J = 7.8, ArH), 7.37 (s, 2H, 
SO2NH2), 3.71 (m, 2H, CONHCH2CH2), 3.14 (t, 1H, J = 7.5, CONHCH2CH2). 13C NMR (75.5 MHz, d6 –DMSO, 25 ºC):  166.1, 147.8, 
144.1, 143.8, 142.5, 141.1, 134.24, 134.16, 133.7, 131.4 (broad), 131.2, 129.1, 125.9, 124.6, 120.1, 119.8, 118.9, 35.6, 26.4.   
ESI-MS calcd for C53H37N6O12S4 [M – 3Na]3- /3 359.0451, found 359.0467. HPLC: (Method B, ESI) Rt = 15.20 min.  
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5-[4-(N-(2-Oxo-2-(5-sulphamoyl-1,3,4-thiadiazol-2-ylamino)ethyl)benzamide)]-10,15,20-tri(4-sulfonylphenyl)-porphyrin, 
[H2TSPP-AZA] or  H2L12 
The title compound was synthesised employing the general sulfonation method (ESI). H2L10 (50.0 mg, 0.057 mmol), conc. H2SO4 
(2 mL). Yield : 48.6 mg, 0.041 mmol, 72 %. 
1H NMR (500 MHz, d6 –DMSO, 25ºC):  8.90 (t, 1H, J = 5.7, CONH), 8.88 (m, 8H, CHpyrr), 8.37 (m, 4H, ArH), 8.21 (d, 6H, J = 8.1, 
ArHSO3Na), 8.07 (d, 6H, J = 8.0, ArHSO3Na), 4.20 (d, 2H, J = 5.6, CONHCH2CONH), -2.91 (s, 2H, ring NH). 13C NMR (125 MHz, d6 –
DMSO, 25 ºC): 174.9, 171.9, 165.9, 165.3, 147.8, 143.9, 141.2, 134.3, 134.2, 133.7, 131.6 (broad), 125.9, 124.2, 119.8, 119.7, 
119.3, 45.5. ESI-MS calcd for C49H32N9O13S5 [M – 3Na]3-/3 371.3580, found 371.3576. HPLC: (Method B, ESI) Rt = 16.11 min.  
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-tri(4-N-methylpyridinium phenyl)-porphyrin tri-iodide, [H2TMePyP-
ABS], H2L10 
H2L10 was synthesised employing the general alkylation method (ESI). The tripyridylporphrin ABS conjugate, synthesis 
described above  (65.0 mg, 0.077 mmol), MeI (109 mg, 47.9 μL, 0.77 mmol), DMF. Yield: 114 mg, 0.090 mmol, 92 %. 
1H NMR (500 MHz, d6 –DMSO, 25ºC): 9.46 (m, 6H, CHpy), 9.11 (m, 8H, CHpyrr), 9.02 (t, 1H, J = 5.4, CONH), 8.99 (m, 6H, CHpy), 8.32 
(d, 2H, J = 8.7, ArH), 8.30 (d, 2H, J = 8.8, ArH), 7.81 (d, 2H, J = 8.3, ArH), 7.56 (d, 2H, J = 8.4, ArH), 7.34 (s, 2H, SO2NH2), 4.70 (m, 
3x3H, 3xN-CH3), 3.70 (m, 2H, CONHCH2CH2), 3.07 (t, 2H, J = 6.9, CONHCH2CH2), -3.06 (m, 1H) 13C NMR (125 MHz, d6 –DMSO, 
25ºC):  166.2, 156.6, 156.5, 144.3, 144.2, 143.9, 143.1, 142.1, 134.4, 134.3, 132.1, 129.3, 126.0, 125.8, 124.1, 121.9, 115.4, 
114.7, 114.5, 111.8, 47.9, 34.5, 25.3. ESI-MS calcd for C53H44N9O3S [M – 3I]3+/3 269.1143, found 269.1143, ESI-MS calcd for 
C53H44N9O3S [M – 3I]3+/2 444.1717, found 444.1708. HPLC: (Method C) Rt = 12.22 min. Elem. Anal.: Found: C; 50.3 %, H; 3.3 %, 
N; 9.8 %. Calc. [H2L10 + MeOH]: C; 49.9 %, H; 3.7 %, N; 9.7 %. 
5-[4-(N-(2-Oxo-2-(5-sulphamoyl-1,3,4-thiadiazol-2-ylamino)ethyl)benzamide)]-10,15,20-tri(4-N-methylpyridiumyl)-
porphyrin tri-iodide, [H2TMePyP-AZA]I3 or H2L13 
Compound H2L13 was synthesised employing the general alkylation method described in ESI. [H2TPyP-AZA] (50.0 mg, 0.038 
mmol), MeI (54.3 mg, 23.8 μL, 0.38 mmol), DMF. Yield: 52.9 mg, 0.040 mmol, 88 %. 
1H NMR (300 MHz, d6 –DMSO, 25 ºC):  9.46 (d, 6H, J = 6.6, CHpy), 9.36 (t, 1H, J = 5.4, CONH), 9.26 - 9.05 (m, 8H, CHpyrr), 8.93 - 
9.03 (m, 6H, CHpy), 8.40 (d, 2H,  J = 8.0, ArH), 8.36 (d, 2H, J = 7.8, ArH), 4.71 (2s, 3x3H, 3xN-CH3), 4.43 (d, 2H, J = 5.8, 
CONHCH2CONH), -3.05 (br s, 1H, ring NH). Mass Spectrum ESI-MS calcd for C49H41N12O4S2 [M – 3I]3+/3 308.0640, found 
308.0621, ESI-MS calcd for C49H41N12O4S2 [M – 3I]3+/2 462.0960, found 462.0993. HPLC: (Method C) Rt = 13.08 min.  
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-tri(4-sulfonylphenyl)-porphyrin(chloroindium (III)), [In(Cl)TSPP-
ABS],  [InClL9] 
The title compound was synthesised employing general metal complexation method 3. H2L9 (40.0 mg, 0.035 mmol), InCl3 (15.5 
mg, 0.070 mmol) in pH 4.5 NaOAc buffer (5 mL). Yield: 29.9 mg, 0.023 mmol, 66 %. 
1H NMR (300 MHz, d6 –DMSO, 25 ºC):  9.07 (t, 1H, J = 5.4, CONH), 8.94 (s, 8H, CHpyrr), 8.29 (s, 4H, ArH), 8.18 (d, 6H, J = 8.0, 
ArHSO3Na), 8.08 (d, 6H, J = 8.2, ArHSO3Na), 7.60 (d, 2H, J = 8.0, ArH), 7.32 (d, 2H, J = 8.0, ArH), 3.65 (m, 2H,CONHCH2CH2), 3.00 (t, 
2H, J = 7.4, CONHCH2CH2) 13C NMR (75.5 MHz, d6 –DMSO, 25 ºC):  166.3, 147.72, 147.69, 147.5, 147.4, 145.9, 144.1, 141.7, 
140.3, 134.2, 134.0, 132.6 (broad), 128.1, 125.9, 125.7, 124.2, 120.8, 120.4, 35.0, 25.0. Mass Spectrum ESI-MS calcd for 
C53H35ClInN6O12S4 [M – 3Na]3-/3 408.3313, found 408.3345. HPLC: (Method B) Rt = 13.23 min.  
5-[4-(N-(4-Sulphamoylphenethyl)benzamide)]-10,15,20-tri(4-N-methylpyridiniumylphenyl)-porphyrin (chloroindium(III)) 
trichloride [In(Cl)TMePyP-ABS]Cl3, [InClL10] 
The title compound was synthesised employing general metal complexation method 3. H2L10 (50.0 mg, 0.039 mmol), InCl3 (17.4 
mg, 0.079 mmol) in pH 4.5 NaOAc buffer (5 mL). Yield: 30.3 mg, 0.027 mmol, 68 %. 
1H NMR (500 MHz, d6 –DMSO, 25 ºC):  9.41 - 9.67 (m, 6H, CHpy), 9.23 - 9.35 (br s, 4H CHpyrr), 9.13 - 9.23 (br s, 3H, CONH, CHpyrr), 
9.02 - 9.11 (br s, 2H, CHpyrr), 8.87 - 9.00 (br s, 6H, CHpy), 8.36 (d, 2H, J = 7.5, ArH), 8.30 (d, 2H, J = 7.5, ArH), 7.81 (d, 2H, J = 8.0, 
ArH), 7.55 (d, 2H, J = 8.0, ArH), 7.36 (s, 2H, SO2NH2), 4.66 - 4.87 (br s, 9H, 3xCH3), 3.69 (m, 2H, CONHCH2CH2), 3.09 - 3.16 (t, 2H, 
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J = 5.7, CONHCH2CH2). 13C NMR (75.5 MHz, d6 –DMSO, 25 ºC):  166.7, 156.6, 156.5, 147.8, 146.5, 146.4, 144.8, 144.3, 144.2, 
142.9, 133.8, 133.3, 132.4, 132.3, 129.8, 126.2, 126.1, 117.3, 116.8, 48.1, 47.9, 35.1, 26.2. Mass Spectrum ESI-MS calcd for 
C53H42ClInN9O3S [M – 3Cl]3+/3 344.7281, found 344.7298. HPLC: (Method C in ESI) Rt = 12.05 min. 
General method for copper-64 radiolabelling 
64Cu-ATSM was prepared from H2-ATSM according to a published method39.2 64CuL was prepared by adding 64Cu(OAc)2(aq) (70 
μL of a 1 MBq/μL solution) to a solution of H2L in DMSO (100 μL, 1 mg/mL). After 20 min stirring at room temperature HPLC 
analysis was carried out using a Platinum C18 column (5 μm particle size, dimensions 250 x 3.0 mm). A 20 min gradient method 
with acetonitrile/water as the mobile phase was used: 0 min 5% MeCN; 10 min 95% MeCN; 15 min 95% MeCN; 18 min 5% 
MeCN, 20 min 5% MeCN. Flow rate = 1.0 mL/min. The radiochemical purity of 64CuL (Rt = mins) was 99%. 0.9% saline solution 
(to < 5% v/v ethanol) for use in PET imaging experiments. The specific activity of the administered tracer was approximately 20 
MBq/mL (0.2 MBq/g of H2L). 
General method for indium-111  radiolabelling 
The ligand was prepared as a 1.0 mg/mL solution in DMSO or distilled water. For indium labeling of water soluble porphyrins 
10 μL of the stock porphyrin solution was diluted with 90 μL of pH 4.5 sodium acetate buffered solution and heated at 115 °C 
for 30 min in an Eppendorf tube in the presence of 20 μL 111InCl3 (< 10 MBq per experiment). For indium labelling of tetraphenyl 
porphyrin derivative 10 μL of the stock solution was diluted with 90 μL of AcOH and heated at 120 °C for 1 h in the presence 
10 μL of a 0.1 M NaOAc (aq.) solution and 20 μL 111InCl3 (< 10 MBq per experiment). AcOH was then driven off under nitrogen 
and the residue re-suspended in 50 μL of CHCl3. The CHCl3 layer was washed repeatedly with 100 μL aliquots of distilled water 
until no further activity was associated with the aqueous washings. For all porphyrin-based compounds the 20 min HPLC 
gradient methods (analytical HPLC) of was performed by one of three methods below: 
General method for technetium-99m radiolabelling 
The radiolabelling was carried out according to the procedure described previously40, using [99mTcO4]- with SnCl2 as the reducing 
agent in sodium carbonate buffer at a temperature of 95 C. Briefly, the ligand (L2 to L6, 0.1 mg) was dissolved in TFA (190 μL) 
and treated with triethylsilane (10 μL) to remove the Trt-group. After removal of the solvent under a stream of N2, sodium 
carbonate solution (80 μL, 0.1 mol/L, pH=9.5) was added to the residue. Next, SnCl2 solution (3 μL, 1 mg/mL) in citrate buffer 
(0.1 mol/L, pH=5.0) and [99mTcO4]- (200 μL, 20 MBq) solution were added, and the reaction mixture was vigorously stirred and 
allowed to react at 95 oC for 1 h. The radiochemical purity and labelling efficiency were determined using radio-HPLC (Method 
C in ESI) or radio-TLC. For radio-TLC, acetonitrile/water (1/1 by volume) was used for the determination of 99mTc-colloid in the 
silica gel TLC (Rf=0) and 2-butanone/ethyl acetate (2/3 by volume) was used for the determination of 99mTc-pertechnetate 
(Rf=1.0) 4. In the cases when the radiochemical purity of the radiotracer did not exceed 95%, the raw product was purified using 
a C18 Sep-PakTM cartridge. The cartridge was pre-treated using ethanol (5 mL), followed by water (5 mL), before the raw 
product was loaded. The loaded cartridge was rinsed twice with water (2×5 mL) to release the 99mTc-pertechnetate and any 
other hydrophilic impurities, and the technetium-labelled product was eluted with ethanol (1 mL). The radiochemical purity of 
the purified radiotracer was then determined using the method described above. All the 99mTc complexes had RCP’s of >98% 
after purification. 
Confocal fluorescence microscopy 
 
HCT116 cells were seeded as monolayers in T75 tissue culture flasks, and cultured in Dulbecco’s Modified   Eagle’s Medium 
(DMEM) supplemented with 10 % foetal bovine serum, L-glutamine, penicillin and streptomycin. Cells were maintained at 37 
°C in a 5 % CO2 humidified atmosphere and grown to approximately 85 % confluence before being split using 2.5 % trypsin. For 
microscopy, cells were seeded onto chambered cover-glass slides and incubated for 12 h to ensure adhesion.  
Porphyrin complexes were prepared as 10 mM solution in DMSO or distilled water, and diluted to 10 μM with DMEM, and 
incubated with the cells at 37 °C. Prior to imaging, the solution was replaced with 1 mL fresh DMEM. Background 
autofluorescence was measured by imaging the cells in 1 mL of DMEM medium only. The fluorescent uptake of Porphyrin 
complexes was imaged by laser-scanning confocal microscopy using a Zeiss LSM 510 META microscope irradiating at 405nm 
with emission filtered between 565 and 615 nm. 
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